W
W. Joseph McCune
Researcher at University of Michigan
Publications - 96
Citations - 9862
W. Joseph McCune is an academic researcher from University of Michigan. The author has contributed to research in topics: Systemic lupus erythematosus & Lupus erythematosus. The author has an hindex of 44, co-authored 90 publications receiving 8628 citations. Previous affiliations of W. Joseph McCune include Vanderbilt University & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: It is indicated that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.
Journal ArticleDOI
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial
Jill P. Buyon,Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Joan T. Merrill,Lisa R. Sammaritano,Michael D. Lockshin,Graciela S. Alarcón,Susan Manzi,H. Michael Belmont,Anca Askanase,Lisa Sigler,Mary Anne Dooley,Joan M. Von Feldt,W. Joseph McCune,Alan Friedman,Jane Wachs,Cronin Me,Michelene Hearth-Holmes,Mark Tan,Frederick Licciardi +22 more
TL;DR: This multicenter, double-blind trial found no significant difference in flare rate between HRT and placebo groups, and health issues specific to women warrant attention and need to be confronted in patients with SLE.
Journal ArticleDOI
A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs
Michael F. Denny,Srilakshmi Yalavarthi,Wenpu Zhao,Seth G. Thacker,Marc R Anderson,Ashley R. Sandy,W. Joseph McCune,Mariana J. Kaplan +7 more
TL;DR: Lupus LDGs are proinflammatory and display pathogenic features, including the capacity to synthesize type I IFNs, which may play an important dual role in premature cardiovascular disease development in systemic lupus erythematosus by simultaneously mediating enhanced vascular damage and inhibiting vascular repair.
Journal ArticleDOI
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace,William Stohl,Richard Furie,Jeffrey R. Lisse,James D. McKay,Joan T. Merrill,Michelle A. Petri,Ellen M. Ginzler,W. Winn Chatham,W. Joseph McCune,Vivian Fernandez,Marc Chevrier,Z. John Zhong,William W. Freimuth +13 more
TL;DR: Belimumab was biologically active and well tolerated and the effect of belimumab on the reduction of SLE disease activity or flares was not significant, however, serologically active SLE patients responded significantly better to belicumab therapy plus SOC than to SOC alone.
Journal ArticleDOI
Combined oral contraceptives in women with systemic lupus erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: This study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable and is within the prespecified 9 percent margin for noninferiority.